BIOCRYST PHARMACEUTICALS INC (BCRX) › Operating Cash FlowBIOCRYST PHARMACEUTICALS INC (BCRX) — Operating Cash FlowAnnual figures by period end, from SEC filings.2009-12-31: -$16.22M2010-12-31: -$28.55M2011-12-31: -$32.25M2012-12-31: -$37.40M2013-12-31: -$26.53M2015-12-31: -$13.12M2016-12-31: -$53.44M2017-12-31: -$41.14M2018-12-31: -$92.56M2019-12-31: -$89.58M2020-12-31: -$135.11M2021-12-31: -$142.16M2022-12-31: -$161.85M2023-12-31: -$95.14M2024-12-31: -$52.02M2025-12-31: $347.37M$347.37M2009-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31$347.37M—2026-02-26From 2025-01-012024-12-31-$52.02M—2026-02-26From 2024-01-012023-12-31-$95.14M—2026-02-26From 2023-01-012022-12-31-$161.85M—2025-02-25From 2022-01-012021-12-31-$142.16M—2024-02-27From 2021-01-012020-12-31-$135.11M—2023-02-27From 2020-01-012019-12-31-$89.58M—2022-02-28From 2019-01-012018-12-31-$92.56M—2021-03-01From 2018-01-012017-12-31-$41.14M—2020-03-13From 2017-01-012016-12-31-$53.44M—2019-03-14From 2016-01-012015-12-31-$13.12M—2018-03-12From 2015-01-012013-12-31-$26.53M—2014-03-10From 2013-01-012012-12-31-$37.40M—2014-03-10From 2012-01-012011-12-31-$32.25M—2014-03-10From 2011-01-012010-12-31-$28.55M—2013-03-11From 2010-01-012009-12-31-$16.22M—2012-03-06From 2009-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)